Early Health Focus Define Ventures specializes in early-stage digital health companies with a sizable focused AUM of $800 million, presenting a strong appetite for seed to Series B investments. This suggests sales opportunities around scalable health tech solutions, regulatory compliance support, and go-to-market strategies tailored to early-stage ventures.

Strategic Partnerships Recent investments in AI-driven and health IT platforms (Luminai, Hyro, Layer Health, 9amHealth) indicate a preference for tech-enabled healthcare operations, enterprise automation, and virtual care. Identify partnerships that enhance provider workflows, patient engagement, and data interoperability to align with their portfolio.

Experienced Leadership With high-profile venture partners joining the firm (Carolyn Magill from Aetion and Bruce Broussard from Humana), Define Ventures signals a strong strategic network in health tech and payer ecosystems. Leverage introductions, co-selling, and collaborative pilots with health systems and value-based care initiatives.

Healthcare Tech Stack Current tech footprint includes AWS, Kubernetes, NoSQL, eClinicalWorks, and Office 365, pointing to a readiness for cloud-scale health IT deployments and integration projects. Position cloud-native, secure data solutions, interoperability adapters, and modern DevOps/observability tools as value adds.

Growth Potential Funding activity and notable exits ($22B exit value from portfolio) underline a strong exit-oriented mindset and scale-up potential. Target growth-stage enablement like go-to-market acceleration, clinical data leverage, and direct-to-consumer health brands that can capture large market share.